Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
AstraZeneca
Merck
Moodys

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRANEXAMIC ACID

» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Tranexamic Acid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00588133 A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery Completed Mayo Clinic Phase 3 2004-01-01 Tranexamic acid is administered intravenously to prevent bleeding associated with cardiac surgery and cardiopulmonary bypass. We have developed an assay for tranexamic acid. We have developed an alternative dosing schedule for tranexamic acid. The objective of this preliminary study is to determine if this new dosing schedule can achieve the desired plasma concentration of tranexamic acid and reduce intra and inter patient variability in tranexamic acid plasma concentrations relative to the current dosing schedule.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Tranexamic Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00111215 Treatment and Management of Women With Bleeding Disorders Completed Centers for Disease Control and Prevention N/A 2001-01-01 The purpose of the study is to determine whether oral contraceptives, desmopressin acetate, and/or tranexamic acid are effective in the treatment of women with menorrhagia who are diagnosed with a bleeding disorder.
NCT00147862 Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery? Completed Tata Memorial Hospital Phase 3 2005-05-01 To Study whether infusion of Tranexamic Acid (a synthetic antifibrinolytic agent) reduces blood loss during head and neck surgery.
NCT00279578 Clot Formation and Clot Stability in Patients With Severe Haemophilia A Completed University of Aarhus N/A 2006-01-01 In the present study we are examining the clot formation and clot stability in patients with severe haemophilia A after they receive recombinat factor VIII and after addition of tranexamic acid. Our hypothesis is that addition of tranexamic increases the clot stability. The perpective of the study is to document whether it is relevant to use traneksamic acid in surgery in patients with severe haemophilia A.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tranexamic Acid

Condition Name

Condition Name for Tranexamic Acid
Intervention Trials
Blood Loss 23
Tranexamic Acid 17
Hemorrhage 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tranexamic Acid
Intervention Trials
Hemorrhage 143
Postpartum Hemorrhage 33
Osteoarthritis 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tranexamic Acid

Trials by Country

Trials by Country for Tranexamic Acid
Location Trials
United States 152
Canada 34
China 27
Egypt 23
France 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tranexamic Acid
Location Trials
New York 19
California 12
Pennsylvania 10
Illinois 7
Michigan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tranexamic Acid

Clinical Trial Phase

Clinical Trial Phase for Tranexamic Acid
Clinical Trial Phase Trials
Phase 4 129
Phase 3 90
Phase 2/Phase 3 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tranexamic Acid
Clinical Trial Phase Trials
Not yet recruiting 117
Recruiting 112
Completed 108
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tranexamic Acid

Sponsor Name

Sponsor Name for Tranexamic Acid
Sponsor Trials
Aswan University Hospital 16
Cairo University 9
London School of Hygiene and Tropical Medicine 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tranexamic Acid
Sponsor Trials
Other 492
Industry 23
U.S. Fed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Dow
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.